31
>
Significant Cost Savings with Kinetex 1.7 µm
Column: Kinetex 1.7 µm C18
Dimensions: 100 x 2.1 mm
Part No.: 00D-4475-AN
Mobile Phase: A: 5 mM Ammonium formate pH 3.25 / Acetonitrile (95:5)
B: 5 mM Ammonium formate pH 3.25 / Acetonitrile (10:90)
Gradient: Time (min)
0.0
1.5
3.0
5.0
6.0
6.1
% B
30
50
56.3
95
95
30
Flow Rate: 0.4 mL/min
Temperature: 50 °C
Detection: PDA 210-300 nm, extracted channel 280 nm
Instrument: Waters
®
ACQUITY
®
equipped with PDA
Sample: 1. Antidepressant drug (containing an HCl salt)
2. Hormone therapy #1 (containing a salt)
3. SERM drug (containing basic functional group)
4. CNS drug (containing basic functional group)
5. PPI drug (containing basic functional group)
6. CNS drug (containing basic functional group)
7. CNS drug (containing basic functional group)
8. Hormone therapy #2 (neutral)
9. Oral contraceptive hormone #1 (neutral)
10. Hormone therapy #3 (neutral)
11. Oral contraceptive hormone #2 (neutral)
12. Hormone therapy #4 (neutral)
13. Oral contraceptive hormone (neutral)
14. Hormone therapy #5 (neutral)
15. Hormone therapy #6 (acetate salt of 14)
16. Immunosuppressant drug (macromolecule, containing
basic functional group)
Waters and ACQUITY are registered trademarks of Waters Corporation. Phenomenex is not affiliated with Waters Corporation.
1
2
3
4
5
6
7
89 10
11
12
13 14
15
16
19794
AU
1
0
2
3
4
5
min
-0.000
0.010
0.020
0.030
0.040
0.050
0.060
0.070
0.080
App ID 19794
It has been shown that the
1.7 µm
Kinetex 100 x 2.1 mm column
was capable of resolving 16 dif-
ferent chemical entities with a 6
minute run time. This new analyti-
cal method will be used to replace
16 older methods thereby facilitat-
ing an
annualised cost saving
for the site of 320,000
A. Charles, et. al., Pfizer Grange Castle,
Grange Castle Business Park, Clondalkin,
Dublin Republic of Ireland
Phenomenex
l
WEB: www.phenomenex.com